Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02965326 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

Study acronym: BIO-CFTR
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 12, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (43)v4
  2. Primary completion date: Mar 2020 to Mar 2026v3 Show 4 more changesShow less
    • Primary endpoint revised
    • Study completion date: Oct 2020 to Oct 2026
    • Secondary endpoints: 1 to 43
    • Site contact updated
  3. Site details revisedv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.
Trial Details
NCT Number NCT02965326
Lead Sponsor Hôpital Necker-Enfants Malades
Collaborators: Association Mucoviscidose-ABCF2, Vaincre la Mucoviscidose
Conditions
(from sponsor)		 Cystic Fibrosis
Related terms Cystic Fibrosis
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov